Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions
Open Access
- 26 September 2021
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 110 (5) , 1311-1317
Abstract
The relevance of biological therapies for an increasing number of conditions is on the rise. Following the expiry of the initial period of market exclusivity, many of these successful therapies have seen the arrival of biosimilars on the market. The clear identification of the precise medicine responsible for an adverse drug reaction (ADR) report is an important element for pharmacovigilance, allowing timely detection of potential product-specific safety signals. We looked at the identifiability of biologicals up to the level of commercial product name in ADR reports received from European clinical practice between 2011 and December 2019. A good level of identification (91.5%) was observed overall, but at the same time a downward trend was observed in the last 5 years. This reduction in the level of identifiability of biological products (originators and biosimilars) at the commercial name level in general was driven by 5 widely used substances, while the identification of all other biologics stayed consistent over time (at over 90%). We observed that those 5 substances were used mostly within oncology. The introduction of the first biosimilar in the market did not appear to affect their identifiability. These results show that although the general level of identification at the commercial product name level in ADRs in Europe is robust and generally stable over time, decreasing trends can be down to a few commonly used substances which need to be monitored to reverse the trend.Keywords
This publication has 22 references indexed in Scilit:
- Interchangeability of Biosimilars: A European PerspectiveBioDrugs, 2017
- Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documentsCurrent Medical Research and Opinion, 2016
- Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR ReportsDrug Safety, 2015
- The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation studyPharmacoepidemiology and Drug Safety, 2015
- Traceability of biologicals: present challenges in pharmacovigilanceExpert Opinion on Drug Safety, 2014
- Similar Names for Similar BiologicsBioDrugs, 2014
- Pharmacovigilance and biosimilars: considerations, needs and challengesExpert Opinion on Biological Therapy, 2013
- Acceptable changes in quality attributes of glycosylated biopharmaceuticalsNature Biotechnology, 2011
- Detection, verification, and quantification of adverse drug reactionsBMJ, 2004
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002